Core Viewpoint - The article discusses the implementation of the first commercial insurance innovative drug directory in China, highlighting the challenges and opportunities for innovative drugs to enter hospitals and outpatient settings under the new policies [3][4][6]. Group 1: Policy Implementation and Impact - The "three exclusions" policy allows innovative drugs included in the commercial insurance directory to be billed separately for inpatient cases, not affecting the bundled payment limits [3][6]. - As of January 8, at least 28 provinces have issued notifications regarding the execution of the national drug directory and the commercial insurance innovative drug directory [6]. - The sales data from the National Healthcare Security Administration indicates that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most had already stocked these drugs prior to the directory's release [6][7]. Group 2: Challenges in Outpatient Use - The outpatient use of commercial insurance innovative drugs remains largely unregulated, with no clear incentives established for outpatient prescriptions [4][10]. - The article notes that while inpatient use may be supported by the "three exclusions" policy, outpatient scenarios face significant barriers, including a lack of payment guarantees from commercial insurance products [10][11]. - The need for clearer guidelines and incentives for outpatient use is emphasized, as many innovative drugs, particularly for cancer and Alzheimer's treatment, are typically administered in outpatient settings [10][11]. Group 3: Market Dynamics and Future Outlook - The article suggests that the success of commercial insurance innovative drugs in hospitals will depend on balancing interests among stakeholders and creating differentiated plans based on local healthcare financing conditions [11][12]. - There is a call for establishing specific standards for exceptional case applications to ensure that patients using commercial insurance innovative drugs are not competing for limited resources with those using nationally negotiated drugs [12][13]. - The potential for hospitals to receive more definitive incentives through "exceptional payments" is highlighted, as this could significantly impact the market volume of commercial insurance innovative drugs [13][14]. Group 4: Retail Pharmacy Integration - The National Healthcare Security Administration has proposed supporting retail pharmacies in stocking drugs from the commercial insurance innovative drug directory, which could enhance access to these medications [15][16]. - However, concerns remain regarding how pricing negotiations and reimbursement rules will be implemented, which could affect the willingness of commercial insurance companies to include these drugs in their coverage [15][16]. - The article stresses the importance of aligning the commercial insurance innovative drug directory with existing healthcare policies to build confidence among healthcare providers in prescribing these medications [16].

Core Viewpoint - The implementation of the first version of the commercial insurance innovative drug directory has begun, with significant implications for the use of innovative drugs in hospitals and outpatient settings, particularly under the "three exclusions" policy [1][3][7]. Group 1: Policy Implementation and Impact - The "three exclusions" policy allows innovative drugs included in the commercial insurance directory to be reimbursed separately from the bundled payment for hospital cases, which is seen as a major benefit for the inclusion of these drugs in hospitals [1][3]. - As of January 8, at least 28 provinces have issued notifications to implement the 2025 version of the national drug directory and the commercial insurance innovative drug directory, indicating a broad acceptance of these policies [3][4]. - The sales data from the National Medical Insurance Administration shows that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most of these were completed before the directory was published [3][4]. Group 2: Challenges in Drug Utilization - There is uncertainty regarding the allocation of special case approvals for commercial insurance innovative drugs, as these approvals are limited to a small percentage of total cases, which may restrict access for patients [8][9]. - The outpatient use of commercial insurance innovative drugs remains largely unregulated, with no existing incentives or policies to support their prescription in outpatient settings [6][12]. - The lack of clear guidelines for the inclusion of commercial insurance innovative drugs in hospital formularies is hindering their adoption compared to nationally negotiated drugs [4][5]. Group 3: Market Dynamics and Future Directions - The market for commercial insurance innovative drugs is expected to grow, but many stakeholders remain cautious due to unresolved issues regarding prescription and payment processes [2][6]. - There is a call for clearer standards and collaboration among departments to ensure the effective use of commercial insurance innovative drugs without being subject to self-payment rate assessments [8][9]. - The potential for outpatient pharmacies to stock commercial insurance innovative drugs is being explored, with some regions already supporting this initiative, but concerns about the integration of outpatient prescriptions into hospital billing remain [11][12].

Core Insights - The commercial insurance innovative drug directory has been officially implemented since January 1, with the inclusion of drugs like Daratumumab β injection, but outpatient incentives for these drugs remain in a policy vacuum [1][2] - The "three exclusions" policy is seen as a significant but challenging measure to facilitate the entry of commercial insurance innovative drugs into hospitals [1][3] - There is a lack of clarity regarding the implementation details for the entry of commercial insurance innovative drugs into hospitals, which limits the ability of medical institutions to stock a wider variety of these drugs [4][5] Group 1 - The first version of the commercial insurance innovative drug directory was launched on January 1, and it includes specific drugs that can be reimbursed separately from the bundled payment system [1] - As of January 8, at least 28 provinces have mandated local medical institutions to hold pharmacy meetings by the end of February to discuss the integration of commercial insurance innovative drugs [2] - The "three exclusions" policy aims to allow innovative drugs to be used in hospitals without affecting the bundled payment system, but its practical implementation remains uncertain [3][7] Group 2 - The entry of commercial insurance innovative drugs into hospitals can either be through inclusion in special drug directories or by facilitating their hospital entry pathways [3] - Recent data shows that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most of these were pre-configured before the directory's release [3][4] - The sales of commercial insurance innovative drugs are highly concentrated in a few products, particularly those used for Alzheimer's treatment [3] Group 3 - There are currently no specific assessment indicators for the hospital configuration of commercial insurance innovative drugs, unlike the established metrics for national negotiated drugs [4] - Some provinces have clarified that the use of national negotiated drugs will not be included in certain performance assessment metrics for public medical institutions, but it is unclear if this applies to commercial insurance innovative drugs [5] - The transition from hospital entry to patient medication involves prescription and payment processes, which currently face significant bottlenecks, especially in outpatient settings [6] Group 4 - The "three exclusions" policy is expected to be crucial for expanding the hospital sales of commercial insurance innovative drugs, but balancing interests among stakeholders is necessary for effective implementation [7] - A common approach to support the use of innovative drugs in hospitals is to open a "special case negotiation" green channel, but the limited application quota raises concerns about accessibility for commercial insurance innovative drugs [8] - The implementation of "exclusion payment" mechanisms is seen as a more definitive incentive for hospitals to use innovative drugs, but current policies primarily favor national negotiated drugs [9] Group 5 - The commercial insurance innovative drug directory's initial week saw sales primarily occurring in medical institutions, but the market potential remains limited due to the nature of the drugs included [11] - There is a push for retail pharmacies to stock commercial insurance innovative drugs, but concerns about prescription practices and reimbursement processes persist [12] - Future efforts should focus on aligning the commercial insurance innovative drug directory with the national insurance system to enhance confidence in the use of these drugs in hospitals [12]

Core Insights - The article discusses the recent implementation of the commercial health insurance innovative drug directory and the challenges it faces in terms of hospital procurement, prescription issuance, and payment processes [1][15] - The "three exclusions" policy is highlighted as a crucial factor for facilitating the entry of innovative drugs into hospitals, which includes exemptions from basic medical insurance self-payment rates, collection of alternative products, and payment by disease category [2][18] Group 1: Implementation of the Commercial Health Insurance Directory - As of December 8, following the national medical insurance negotiations, at least 20 provinces have issued notifications for the online procurement of the commercial health insurance innovative drug directory [2][15] - The directory includes 19 high-value innovative drugs, but the industry is concerned about how these drugs will navigate the challenges of hospital entry, prescription issuance, and payment [2][15] Group 2: The "Three Exclusions" Policy - The "three exclusions" policy is seen as a key to overcoming the barriers to drug entry and prescription issuance, allowing commercial insurance directory drugs to bypass certain cost control measures of basic medical insurance [2][18] - However, there are currently no clear guidelines for the implementation of the "three exclusions" policy, leading to skepticism among hospital pharmacists regarding their interest in procuring these drugs without incentives [2][16] Group 3: Challenges in Hospital Procurement - The DRG (Diagnosis-Related Group) exclusion is identified as the most complex aspect of the "three exclusions" policy, which is essential for allowing hospitals to procure commercial health insurance directory drugs without financial loss [3][19] - Hospitals face significant pressure regarding drug management costs, and without proper incentives, their interest in purchasing these innovative drugs remains limited [2][16] Group 4: Comparison with National Negotiated Drugs - Despite the introduction of favorable policies for national negotiated drugs, they still face slow integration into hospitals, with only a limited number of these drugs being routinely stocked in hospitals [8][22] - The article suggests that the experience of Shanghai's "new and excellent drug and device" list could provide insights for improving the entry of commercial health insurance directory drugs into hospitals [9][23] Group 5: Alternative Distribution Channels - There is a suggestion that pharmacies could serve as an alternative distribution channel for the commercial health insurance directory drugs, similar to previous attempts with national negotiated drugs [12][25] - The success of this approach would depend on balancing patient access to medications with the insurance companies' risk management strategies [12][26] Group 6: Market Growth and Policy Synergy - The growth of the commercial health insurance market is crucial for the successful implementation of the directory, as it requires a sufficient market demand to support hospital procurement and prescription issuance [13][26] - The interaction between the "three exclusions" policy and the commercial health insurance market will be key to fostering a positive cycle that promotes the development of innovative drugs [13][26]

Core Viewpoint - The Commercial Health Insurance Innovative Drug Directory aims to provide a list of high-value innovative drugs that exceed basic medical insurance coverage, effective from January 1, 2026 [1][2]. Group 1: Overview of the Innovative Drug Directory - The directory includes 19 drugs focusing on three key areas: high-priced cancer treatments (5 Car-T cell therapy drugs), rare disease medications, and new targeted therapies for severe cancers [1]. - The directory is intended for reference by commercial health insurance and medical mutual aid systems, highlighting the importance of these drugs for patients with limited treatment options [1]. Group 2: Policy Implications - Drugs listed in the directory are not eligible for reimbursement under basic medical insurance, but the National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate their use in hospitals [2]. - This policy alleviates concerns for hospitals regarding the use of innovative drugs, allowing for direct prescription and reimbursement through commercial insurance, thus bypassing previous complexities [2]. Group 3: Insurance Product Adaptation - Some commercial insurance products, such as certain惠民保 plans, have begun to incorporate drugs from the directory, offering increased reimbursement rates for hospital use of these drugs [2]. - Insurance companies are currently assessing how to integrate the directory's drugs into existing medical insurance products, with some already including specific innovative drugs as optional or mandatory coverage [3]. Group 4: Consumer Guidance - Consumers are advised to carefully review insurance contracts for coverage details, including specific drug lists, reimbursement rates, and any limitations on pharmacies or hospitals [4]. - Understanding the reimbursement process for innovative drugs is crucial, as it often involves specific purchasing locations, prescriptions from specialists, and prior authorization from insurance companies [4]. - Consumers should balance the cost of premiums with the level of coverage provided, considering personal health conditions and financial capabilities when deciding on insurance products that include innovative drug coverage [5].

Core Insights - The article discusses the financial burden of innovative cancer treatments in China, highlighting the challenges patients face in affording these high-cost medications, which can reach hundreds of thousands of yuan annually [1][2] - The "White Paper on Multi-Payment for Innovative Drugs and Devices (2025)" indicates that in 2024, China's innovative drug sales are expected to reach 162 billion yuan, with a significant portion of costs falling on patients and limited contributions from commercial health insurance [1][2][5] Payment Structure - In 2024, the expected sales of innovative drugs in China will be 162 billion yuan, with the medical insurance fund covering approximately 71 billion yuan (44%), personal cash payments around 78.6 billion yuan (49%), and commercial health insurance contributing only 12.4 billion yuan (7.7%) [1][2][5] - The current payment structure shows a high burden on individuals and insufficient support from commercial health insurance, which is critical for the sustainable development of innovative drugs [2][5] Role of Commercial Health Insurance - The article emphasizes that while "Hui Min Bao" (a popular supplementary insurance) has grown rapidly, it primarily covers basic medical expenses and has limited capacity to support high-value innovative drugs due to its low premium structure [3][5][6] - Experts suggest that commercial health insurance needs to expand its coverage and payment capabilities to alleviate the financial burden on patients and support the innovative drug industry [4][6][10] Policy Developments - Recent measures from the National Medical Insurance Administration aim to enhance the role of commercial health insurance in supporting innovative drugs, proposing a multi-layered payment system that includes charity donations and mutual aid [8][9] - The "Three Exclusions" policy allows commercial health insurance to cover innovative drugs without being counted against basic medical insurance metrics, thus providing more flexibility for hospitals and insurers [9][10] Future Directions - The article suggests that the future of innovative drug payments will involve a collaborative model where basic insurance covers essential drugs, supplementary insurance addresses high-value drugs, and commercial health insurance fills the gaps [6][10] - As Chinese innovative drugs gain international approval, there is potential for cross-border insurance products to support these drugs in overseas markets, although challenges remain in terms of recognition and reimbursement [17][19]